CNBC's Jim Cramer on Thursday recommended that investors not base portfolio decisions solely off macroeconomic trends, like new employment data or interest rates."I don't want to be bound by the four walls of the PMIs, the PPIs, the PCDEs, the GDPs. We don't want ETFs where we buy the bad along with the good, and we certainly don't want to worry about every tick in interest rates," he said. "You know why? One, because that's a sucker's game. You're letting the macro control your thinking...Two is Eli Lilly. ...

Key TakeawaysThe S&P 500 rebounded on Thursday, Aug. 8, 2024, jumping 2.3% as fresh jobless claims data helped ease worries about the economy.Eli Lilly shares popped after the drugmaker reported better-than-expected earnings for the second quarter, boosted by the popularity of its weight-loss drugs.Electronic technology manufacturer Parker-Hannifin reported strong demand in its aviation services business, and its shares took off. Major U.S. equities indexes rallied after jobless claims data released Thursda ...

Eli Lilly (LLY) shares soared Thursday, after the company's second-quarter earnings surpassed expectations on booming demand for its weight-loss drugs and executives provided updates on production capacity and more. Demand for Weight-Loss Drugs Fuels Growth Sales of Eli Lilly weight-loss drug Mounjaro more than tripled year-over-year to $3.09 billion in the quarter. Sales of Zepbound, another weight-loss drug, have reached $1 billion in less than a year since the drug received FDA approval in November 2 ...

Eli Lilly and Company (NYSE:LLY) Q2 2024 Results Conference Call August 8, 2024 11:30 AM ET Company Participants Joe Fletcher - Senior Vice President-Investor Relations Dave Ricks - Chief Executive Officer Gordon Brooks - Group VP, Controller & Corporate Strategy and Interim CFO Dan Skovronsky - Chief Scientific Officer and President-Lilly Immunology Patrik Jonsson - President-Lilly Diabetes and Obesity and Lilly USA Ilya Yuffa - Executive Vice President Conference Call Participants Seamus Fernandez - Gugge ...

Eli Lilly ((LLY) reported strong quarterly results on Thursaday morning, with revenue increasing 36%, driven primarily by the success of Mounjaro, Zepbound, and Verzenio. The company also saw a significant increase in earnings per share (EPS), up 68% year-on-year and eclipsing analysts’ estimates by 42%.Eli Lilly raised its full-year revenue guidance by $3 billion and increased its EPS guidance. Additionally, the company highlighted major progress in its pipeline, including the approval of Kisunla for Alzhe ...

How fast must Lilly grow to justify a 54.5 P/E ratio?Stock of Eli Lilly (LLY 8.32%), the famed Indianapolis pharmaceuticals giant, jumped 8.3% through 12:45 p.m. ET after the company reported a massive earnings beat this morning.Heading into the quarter, Wall Street analysts forecast Lilly would earn $2.60 per share on sales of $9.9 billion. Instead, Lilly reported a blockbuster $3.92-per-share profit, and sales of $11.3 billion. Eli Lilly's Q2 earningsHow did Lilly do that? Three words: Mounjaro, Zepbound, ...

Eli Lilly and Company (LLY) reported second-quarter 2024 adjusted earnings per share (“EPS”) of $3.92, which comprehensively beat the Zacks Consensus Estimate of $2.64 per share. Earnings rose 86% year over year.Revenues of $11.3 billion rose 36% year over year. Total revenues beat the Zacks Consensus Estimate of $9.83 billion.Higher volumes of drugs like Mounjaro, Zepbound, Verzenio and Taltz made up for a difficult comparison with the year-ago quarter, which included revenues from the sale of Baqsimi righ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 COMMISSION FILE NUMBER 001-6351 ELI LILLY AND COMPANY (Exact name of Registrant as specified in its charter) Indiana 35-0470950 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) Lilly Corporate Center, Indianapolis, Indiana 46285 (Address and zip ...

Eli Lilly and Co.'s second-quarter earnings surpassed Wall Street estimates as sales of its blockbuster weight-loss drugs soared.  "Mounjaro, Zepbound and Verzenio led our strong financial performance in the second quarter as we advanced our manufacturing expansion agenda," CEO David Ricks said in a statement. During the three-month period, Lilly notched $11.3 billion in global revenue, surpassing the $9.92 billion that Wall Street expected. Adjusted earnings per share came in at $3.92, which also beat Wall ...

Eli Lilly (LLY) reported $11.3 billion in revenue for the quarter ended June 2024, representing a year-over-year increase of 36%. EPS of $3.92 for the same period compares to $2.11 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $9.83 billion, representing a surprise of +14.99%. The company delivered an EPS surprise of +48.48%, with the consensus EPS estimate being $2.64.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how th ...